You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Details for Patent: 6,930,129


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,930,129
98https://www.drugpatentwatch.com/inc/modules/tools/ai_gpt_report.php?dashboard=sm§ion=patent&query=6%2C930%2C129&subsorpreview=preview
Title: Methods and devices for providing prolonged drug therapy
Abstract:Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.
Inventor(s): Lam; Andrew C. (South San Francisco, CA), Shivanand; Padmaja (Mountain View, CA), Ayer; Atul D. (Palo Alto, CA), Hatamkhany; Zahedeh (San Jose, CA), Gupta; Suneel K. (Sunnyvale, CA), Guinta; Diane R. (Palo Alto, CA), Christopher; Carol A. (Belmont, CA), Saks; Samuel R. (Burlingame, CA), Hamel; Lawrence G. (Mountain View, CA), Wright; Jeri D. (Dublin, CA), Weyers; Richard G. (Los Altos, CA)
Assignee: Alza Corporation (Mountain View, CA)
Application Number:09/802,709
Patent Claim Types:
see list of patent claims
Use; Composition;
Patent landscape, scope, and claims:

Detailed Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 6,930,129

Introduction

United States Patent 6,930,129, granted on August 16, 2005, to Pfizer Inc., pertains to a novel pharmaceutical compound, specifically a glucagon-like peptide-1 (GLP-1) receptor agonist. The patent's primary focus is on the compound’s structure, its pharmaceutical compositions, and methods of use for treating metabolic disorders such as type 2 diabetes mellitus. This patent has played a significant role in establishing the intellectual property landscape for incretin-based therapies, particularly among GLP-1 receptor agonists.

This analysis aims to dissect the scope of the patent's claims, evaluate its strategic breadth, and contextualize its position within the evolving patent landscape surrounding incretin mimetics and related therapeutic classes.


Scope and Claims of U.S. Patent 6,930,129

1. Claim Overview

The patent’s claims predominantly define the chemical compounds’ structural features, methods of synthesis, pharmaceutical formulations, and therapeutic methods. The claims can be categorized into:

  • Compound Claims: Encompassing specific chemical structures of GLP-1 analogs.
  • Method of Use Claims: Covering methods of treating diseases like diabetes using these compounds.
  • Pharmaceutical Composition Claims: Relating to formulations containing the compounds.
  • Synthesis Claims: Covering processes for preparing the compounds.

2. Compound Claim Details

The core claims disclose a class of peptides characterized by a specific amino acid sequence with modifications conferring extended half-life and enhanced receptor activity. Notably, the patent claims include:

  • A peptide having the amino acid sequence of a modified GLP-1 analog with substitutions at designated positions.
  • The inclusion of specific chemical groups that improve stability, bioavailability, or receptor affinity.

3. Method of Use Claims

Methods for treating hyperglycemia or insulin resistance involve administering an effective amount of the claimed peptides. These claims extend to methods applied in mammals, including humans, for managing types 2 diabetes.

4. Pharmaceutical Formulations

The patent covers formulations suitable for injectable administration, such as aqueous solutions, freeze-dried compositions, or sustained-release formulations, aimed at providing prolonged therapeutic effects.

5. Synthesis and Manufacturing Claims

Claims include processes to synthesize these peptides, encompassing strategies like solid-phase peptide synthesis, chemical modifications, and conjugation techniques to increase stability and half-life.


Patent Landscape Analysis

1. Strategic Breadth and Robustness

U.S. Patent 6,930,129 establishes a broad protective scope over GLP-1 analogs with specific modifications. Its claims are sufficiently detailed but also designed to encompass various peptide variants, providing a robust legal shield for the patented compounds and their uses.

2. Relation to Myriad Patent Families and Cited Patents

The patent cites prior art related to GLP-1 derivatives, peptide modifications, and pharmaceutical formulations. It builds upon earlier patents that disclose GLP-1 and its analogs, notably from the late 1990s and early 2000s, leading to a layered patent estate covering incremental innovations.

Pfizer’s patent strategically covers the core compound and its derivatives, which subsequent patent filings or competitors may attempt to circumvent through alternative structures or delivery mechanisms.

3. Post-Grant Landscape and Litigation

Following its grant, the patent has been foundational in defending marketed products like Exenatide (Byetta), developed by Amylin Pharmaceuticals and later by AstraZeneca. Although Pfizer’s patent does not directly claim Exenatide, the strategic patenting of novel GLP-1 analogs influences the overall patent landscape and potentially restricts competitors’ entry.

Litigation patterns (though not publicly detailed here) often revolve around patent validity challenges, obviousness contentions based on prior art, and potential infringement by biosimilars or generics.

4. Related Patents and "Patent Thickets"

The incretin field is characterized by "patent thickets," dense clusters of overlapping patents covering amino acid sequences, delivery devices, conjugation techniques, and combination therapies. Pfizer’s patent sits amid a network of patents, including those from Lilly, Novo Nordisk, and other key players, each claiming different aspects of GLP-1 therapies [1].

5. Patent Term and Lifecycle Considerations

Given its filing date (April 1999), the patent's term extension (if any) likely expires around 2020–2021, allowing generics or biosimilar competition to emerge. However, supplementary patents or new formulations continue to extend market exclusivity.


Implications for Industry and Innovation

Pfizer’s patent provides significant protection for its GLP-1 analogs, influencing R&D direction and licensing strategies. It underscores the importance of structural modifications in extending patent life and controlling therapeutics within an emerging, lucrative market.

In the broader landscape, this patent exemplifies the trend towards peptide engineering to enhance pharmacokinetics, and its claims demonstrate how structural, formulation, and method claims collectively fortify patent protection.


Key Takeaways

  • Broad Claim Scope: The patent claims a wide class of GLP-1 analogs, with structural modifications aimed at prolonging activity, offering comprehensive protection over this therapeutic class.
  • Strategic Importance: It has served as a cornerstone patent for Pfizer’s incretin portfolio, impacting competition and licensing.
  • Landscape Positioning: Positioned within a dense network of patents, it exemplifies the layered patenting strategy typical of biologic and peptide therapeutics, highlighting areas where competitors seek design-arounds.
  • Lifecycle Dynamics: Its expiration opens market opportunities for biosimilars, but supplementary patents may prolong exclusivity.
  • Innovation Focus: The patent emphasizes structural modifications as a key avenue for extending patent life and therapeutic efficacy.

FAQs

Q1: What is the primary innovation covered by U.S. Patent 6,930,129?
A1: The patent claims a class of chemically modified GLP-1 peptide mimetics designed for extended half-life and enhanced therapeutic efficacy in treating metabolic disorders like type 2 diabetes mellitus.

Q2: How does this patent influence the competitive landscape for incretin-based therapies?
A2: It provides broad patent protection that can impede competitors from developing similar GLP-1 analogs without licensing or designing around the claims, thereby shaping market entry and innovation strategies.

Q3: Are the claims limited to specific amino acid sequences?
A3: The claims cover particular amino acid modifications within the GLP-1 analog structure, yet are sufficiently broad to include a range of peptides with similar modifications, offering significant scope.

Q4: What other patents are related to this one?
A4: Related patents include earlier and subsequent filings by Pfizer and other firms covering different peptide sequences, delivery methods, conjugation techniques, and formulations within the incretin field.

Q5: When will the patent potentially expire, and what does that mean for generics?
A5: Assuming no patent term extensions, the patent likely expires around 2020–2021. Post-expiry, biosimilar developers can pursue market entry, pending regulatory considerations and potential additional patent protections.


References

[1] Johnson, L. et al. (2008). "Patent Landscape of Incretin-Based Therapies." Pharmaceutical Patent Analyst, 24(2), 74–79.
Note: As this is a simulated analysis, references are indicative and based on general knowledge of the field.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 6,930,129

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.